ReviewFrontiers in psychiatry2018
Baclofen and the Alcohol Withdrawal Syndrome-A Short Review.
Review in Frontiers in psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Baclofen for alcohol withdrawal.The Cochrane database of systematic reviews · 2019Pooled it
- Promising strategies for the prevention of alcohol-related brain damage through optimised management of acute alcohol withdrawal: A focussed literature review.Journal of psychopharmacology (Oxford, England) · 2025Review
- A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder.Brain sciences · 2024Review
- Ameliorative effect of diazepam against ethanol-induced mitochondrial disruption in brains of the mice.Toxicology reports · 2023Article
- A Review of the Characteristics of Clinical Trials and Potential Medications for Alcohol Dependence: Data Analysis from ClinicalTrials.gov.Medicina (Kaunas, Lithuania) · 2023Review
- Evaluation of Gabapentin and Baclofen Combination for Inpatient Management of Alcohol Withdrawal Syndrome.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2023Article
- GABAergic signaling in alcohol use disorder and withdrawal: pathological involvement and therapeutic potential.Frontiers in neural circuits · 2023Review
- Preventive Effects of Baclofen but Not Diazepam on Hippocampal Memory and Glucocorticoid Alterations After Prolonged Alcohol Withdrawal in Mice.Frontiers in psychiatry · 2022Article
- Perioperative Management of Alcohol Withdrawal Syndrome.Visceral medicine · 2020Review
- Management of Alcohol Withdrawal in the Emergency Department: Current Perspectives.Open access emergency medicine : OAEM · 2020Review
- Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Article
- Management of Alcohol Withdrawal Syndrome in Patients with Alcoholic Liver Disease.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Alcohol Withdrawal Syndrome (AWS), which may occur with or without delirium, is a frequent consequence of sudden alcohol cessation in patients with moderate to severe Alcohol Dependence Syndrome (ADS). Withdrawal as a result of habituation to alcohol is part of the definition of the Alcohol Dependence Syndrome (ICD10). Since the recognition of Delirium Tremens, in the early nineteenth century, the management of the syndrome, an acute medical emergency, has proven controversial. The barbiturates, chlormethiazole, and recently the safer benzodiazepines transformed the management of these conditions. The benzodiazepines, particularly diazepam and chlordiazepoxide, are now the most used first line agents in the treatment of AWS. In addition, a number of other agents, including baclofen, a GABA-B receptor agonist, have the potential to suppress the alcohol withdrawal syndrome. In this review we review the potential use of baclofen in its role to treat AWS. We summarize initial case reports as well as more recent randomized trials of AWS treatment with baclofen. We conclude that currently there is not enough evidence to support the use of baclofen as a first line treatment for AWS. More research will be needed to determine where baclofen might have a role in second-line management of the Alcohol Withdrawal Syndrome on its own or in combination with benzodiazepines or other agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.